{"DataElement":{"publicId":"12192441","version":"1","preferredName":"Conditioning Regimen Type","preferredDefinition":"The type that indicates the Conditioning Regimen type used prior to transplant.","longName":"SUPPPR_QVAL_CONDREG","context":"CCTG","contextVersion":"1","DataElementConcept":{"publicId":"12192435","version":"1","preferredName":"Procedures Supplemental Qualifiers Dataset Transplant Conditioning Treatment Regimen","preferredDefinition":"A dataset containing supplemental information, specifically non-standard variables, to parent records in the procedures domain._Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).:A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","longName":"12192434v1.00:2224042v1.00","context":"CCTG","contextVersion":"1","ObjectClass":{"publicId":"12192434","version":"1","preferredName":"Procedures Supplemental Qualifiers Dataset Transplant Conditioning","preferredDefinition":"A dataset containing supplemental information, specifically non-standard variables, to parent records in the procedures domain._Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","longName":"C147239:C64468","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procedures Supplemental Qualifiers Dataset","conceptCode":"C147239","definition":"A dataset containing supplemental information, specifically non-standard variables, to parent records in the procedures domain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Transplant Conditioning","conceptCode":"C64468","definition":"Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F048AEA8-1671-261D-E053-731AD00ABB50","latestVersionIndicator":"Yes","beginDate":"2022-12-20","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-12-20","modifiedBy":"MMADDINENI","dateModified":"2022-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2224042","version":"1","preferredName":"Treatment_Regimen","preferredDefinition":"Treatment schedule for the pre-clinical trial / therapeutic experiment describing the dosages of the drug and the times of the treatment.","longName":"C15697","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63F046F-540F-4E81-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-03","endDate":null,"createdBy":"UMLLOADER_CAMOD","dateCreated":"2005-05-03","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F048AEA8-1672-261D-E053-731AD00ABB50","latestVersionIndicator":"Yes","beginDate":"2022-12-20","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-12-20","modifiedBy":"MMADDINENI","dateModified":"2023-01-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"12192437","version":"1","preferredName":"Transplant Conditioning Type","preferredDefinition":"Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection)._Something distinguishable as an identifiable class based on common qualities.","longName":"12192437v1.00","context":"CCTG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Myeloablative","valueDescription":null,"ValueMeaning":{"publicId":"2568580","version":"1","preferredName":"Myeloablative","longName":"2568580v1.00","preferredDefinition":"A conditioning regimen with high doses of chemotherapy or radiation to eliminate host hematopoietic stem cells prior to restitution via transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloablative Conditioning","conceptCode":"C131679","definition":"A conditioning regimen with high doses of chemotherapy or radiation to eliminate host hematopoietic stem cells prior to restitution via transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8F1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-25","modifiedBy":"MMADDINENI","dateModified":"2022-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F049155E-E0B9-347E-E053-731AD00AD367","beginDate":"2022-12-20","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-12-20","modifiedBy":"MMADDINENI","dateModified":"2022-12-20","deletedIndicator":"No"},{"value":"Reduced Intensity","valueDescription":null,"ValueMeaning":{"publicId":"4383037","version":"1","preferredName":"Reduced Intensity","longName":"4383037v1.00","preferredDefinition":"A method of preparation for stem cell transplant that uses less than standard doses of chemotherapy and radiation prior to the transfer of stem cells, with the goal of providing protection against graft vs. host disease, while simultaneously minimizing the toxic effects of the conditioning treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reduced-Intensity Transplant Conditioning Procedure","conceptCode":"C116471","definition":"A method of preparation for stem cell transplant that uses less than standard doses of chemotherapy and radiation prior to the transfer of stem cells, with the goal of providing protection against graft vs. host disease, while simultaneously minimizing the toxic effects of the conditioning treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FDC84AA1-9BFA-FC5A-E040-BB89AD433AD9","latestVersionIndicator":"Yes","beginDate":"2014-07-09","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-07-09","modifiedBy":"MMADDINENI","dateModified":"2022-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F049155E-E0BA-347E-E053-731AD00AD367","beginDate":"2022-12-20","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-12-20","modifiedBy":"MMADDINENI","dateModified":"2022-12-20","deletedIndicator":"No"},{"value":"Other","valueDescription":null,"ValueMeaning":{"publicId":"6424136","version":"1","preferredName":"Other","longName":"6424136","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753441A1-068C-5A23-E053-F662850A6B7A","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-02","changeDescription":null,"administrativeNotes":"2023.2.2 Alt VM added per ticket request CADSR0002006. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F049155E-E0BB-347E-E053-731AD00AD367","beginDate":"2022-12-20","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-12-20","modifiedBy":"MMADDINENI","dateModified":"2022-12-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"12192436","version":"1","preferredName":"Transplant Conditioning Type","preferredDefinition":"Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection)._Something distinguishable as an identifiable class based on common qualities.","longName":"12192436v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transplant Conditioning","conceptCode":"C64468","definition":"Administration of high doses of chemotherapy or radiation therapy, as well as immunosuppressive therapy, to a transplant recipient prior to a bone marrow or hematopoietic stem cell transplant.  Conditioning destroys the patient's abnormal blood cells or cancer, as well as slows the patient's immune response against the donor bone marrow (graft rejection).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F048BF15-6413-27D7-E053-731AD00A9A42","latestVersionIndicator":"Yes","beginDate":"2022-12-20","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-12-20","modifiedBy":"MMADDINENI","dateModified":"2022-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F048BF15-6414-27D7-E053-731AD00A9A42","latestVersionIndicator":"Yes","beginDate":"2022-12-20","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-12-20","modifiedBy":"MMADDINENI","dateModified":"2023-01-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the conditioning regimen type used?","url":null,"context":"CCTG"},{"name":"CCTG CRF TEXT 1","type":"Alternate Question Text","description":"If allogeneic HCT, select the conditioning regimen:","url":null,"context":"CCTG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F04952D7-0CDF-4328-E053-731AD00A152C","latestVersionIndicator":"Yes","beginDate":"2022-12-20","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-12-20","modifiedBy":"MMADDINENI","dateModified":"2023-01-06","changeDescription":null,"administrativeNotes":"12/20/2022- Created CDE-MM","unresolvedIssues":null,"deletedIndicator":"No"}}